Melbourne researchers have shown they can stop leukaemia in its tracks by targeting a protein that puts the handbrake on cancer cell growth.
The researchers discovered that targeting a protein called Hhex could cure acute myeloid leukaemia (AML) in preclinical disease models, and could be a key target for new therapies for human leukaemia.
Dr Ben Shields and Dr Matt McCormack from the Walter and Eliza Hall Institute’s Cancer and Haematology division discovered that loss of the Hhex protein put the handbrake on leukaemia cell growth and division. The protein is a critical factor enabling AML cells to grow uncontrollably, a hallmark of cancer.
AML is an aggressive blood cancer that appears suddenly, grows quickly and has a poor prognosis. Existing treatments for AML are associated with serious side-effects. About three quarters of patients relapse after only a short period of treatment, with a five-year survival rate of just 24 per cent.
Dr McCormack said discovering how AML overcame normal cellular controls on growth and division was a breakthrough in the search for new therapies.
“There is an urgent need for new therapies to treat AML,” said Dr McCormack. “We showed blocking the Hhex protein could put the brakes on leukaemia growth and completely eliminate AML in preclinical models. This could be targeted by new drugs to treat AML in humans.”
He said Hhex was a particularly attractive therapeutic target because it was overproduced in leukaemia and, while essential for leukaemia cell growth, was not needed by healthy blood cells.
“Most existing treatments for AML are not cancer cell-specific, and unfortunately kill off healthy cells in the process,” Dr McCormack said.
“Hhex is only essential for the leukaemic cells, meaning we could target and treat leukaemia without toxic effects on normal cells, avoiding many of the serious side-effects that come with standard cancer treatments. We also know that most people with AML have increased levels of Hhex, often associated with adverse outcomes, further indicating it is an important target for new AML drugs.”
Dr Shields said AML cells switched off the controls that strictly manage cell growth and division. “Every cell has control genes that are activated when a cell is stressed, such as in the early stages of cancer, and stop the damaged cell from reproducing.” Dr Shields said.
While these control genes are still present in AML cells, they are switched off through a process called epigenetic modification. “Hhex works by recruiting epigenetic factors to growth control genes, effectively silencing them. This allows the leukaemia cells to reproduce and accumulate more damage, contributing to the speed of AML progression,” Dr Shields said.
Dr McCormack said drugs that inhibit epigenetic modification had been previously used to treat AML, but caused significant toxicity because their targets were also required for normal blood cell function.
“Unlike the epigenetic factors targeted previously, Hhex only regulates a small number of genes and is dispensable for normal blood cells. This gives us a rare opportunity to kill AML cells without causing many side effects,” said Dr McCormack. “We now hope to identify the critical regions of the Hhex protein that enable it to function, which will allow us to design much-needed new drugs to treat AML.”
The Latest on: Leukaemia
via Google News
The Latest on: Leukaemia
- UAE's coronavirus stem cell therapy treats 5,000 Covid-19 cases, four leukaemia patientson November 29, 2020 at 12:08 am
An innovative coronavirus stem-cell treatment helped 5,000 patients recover from the effects of Covid-19, according to the Abu Dhabi Stem Cell Centre (ADSCC). The large increase was as a resul ...
- Dying mum, 45, ‘told to prove she has leukaemia’ at Costa Coffee after asking to use toilet as she felt unwellon November 28, 2020 at 12:31 am
A DYING mum was allegedly told to prove she had leukaemia after asking to use the toilet in a Costa Coffee. Nicky Hughes, who is currently receiving palliative care after being diagnosed with ...
- Dying nurse told to ‘prove’ her leukaemia by heartless Costa Coffee staff after begging to use their toiletson November 27, 2020 at 8:30 pm
Nicky Hughes claims she was refused access to the Costa Coffee toilets despite fearing she was about to vomit - a side effect from her terminal blood cancer.
- EOTB's Ashley Cain stops daughter Azaylia's tears by singing a song at home amid leukaemia battleon November 26, 2020 at 10:21 am
The Ex On The Beach star, 30, sweetly sang a rendition of I Wanna Be Like You from The Jungle Book and within seconds the tot had stoped crying and was smiling in a clip shared on Thursday.
- Chisom Chukwuneke death: Father reveal how im 2019 WAEC star daughter suffer leukaemia cancer pains during examson November 25, 2020 at 6:22 am
But all dat no fit happun now as di 17-year-old Enugu student die as a result of leukaemia for October 2020. Di grief na one wey di family need to deal with togeda - along with im wife and second ...
- England footballer James Tarkowski surprises leukaemia sufferer, ten, and pal with PlayStation 5 consoleson November 23, 2020 at 4:43 pm
ENGLAND footie star James Tarkowski has delighted a ten-year-old leukaemia sufferer and his pal by handing them the latest PlayStation 5 consoles worth £450 each. The Burnley defender, 28, ...
- Leeds mum of seven-year-old boy fighting leukaemia raising funds for cancer researchon November 22, 2020 at 5:35 pm
Thomas Hebbron, from Roundhay, was diagnosed with T-Cell Acute lymphoblastic leukaemia when he was just five-years-old in February 2019. His mum Gemma Hebbron, 37, has set up a fund with a leading ...
- Hairy Cell Leukaemia Market Outlook, Demand and Scope 2020 to 2023on November 22, 2020 at 3:44 am
Global Hairy Cell Leukaemia Market Research Report published by market insight reports explores the current outlook in Global and key regions from the perspective of Major Players, Countries, Product ...
- Thousands of leukaemia sufferers could be spared chemotherapy thanks to a new two-in-one treatment that’s been found to keep twice as many patients free of the diseaseon November 21, 2020 at 2:24 pm
The newly approved combination of the drugs venetoclax and obinutuzumab, given the green light earlier this month by regulators, allows patients to forgo chemotherapy completely.
- Renal Function Decline With TKI Use in Chronic Myeloid Leukaemiaon November 19, 2020 at 1:36 am
Renal function declines over time with tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukaemia (CML), although it is unclear if the relationship is causal, shows a 10-year study.
via Bing News